Japanese Circulation Journal Vol.65, October 2001 were enrolled. The study design followed that of the PACT trial 8 for the most part (Fig 1) . Eligible patients were randomly assigned by the sealed envelope method to either the primary PTCA group, given 5,000 units intravenous heparin and 182 mg oral aspirin, or to the monteplase group, given 800,000 units intravenous monteplase (approximately half the standard dose) in addition to the same doses of heparin and aspirin. Monteplase is a mutant tissue plasminogen activator (t-PA) developed in Japan that can be given by intravenous injection. 13 It has a longer alpha halflife and rapidly restores the Thrombolysis in Myocardial Infarction (TIMI) 14 flow grade to 2 or 3.
Cardiac catheterization was performed immediately after medication. If the TIMI flow grade in the infarct-related artery (IRA) was 0, 1, or 2 on the first angiogram performed 30 min after medication, PTCA, including stent implantation, was performed (ie, primary PTCA in the primary PTCA group and rescue PTCA in the monteplase group). But in principle, immediate PTCA was not performed and we did not give additional monteplase when TIMI flow grade 3 was achieved. For patients whose angiograms indicated that PTCA was not optimal (10 patients), subsequent therapy was left to the physician's discretion. Reperfusion time was defined as the time from the onset of symptoms until when TIMI flow grade 3 was confirmed angiographically. However, in patients showing an improvement in symptoms and a decrease in ST-segment deviation on the ECG before the first angiogram and in whom TIMI flow grade 3 was confirmed on the first angiogram, reperfusion time was defined as the time when such clinical findings were observed. As adjunctive therapies after reperfusion, 81 mg/day of aspirin was continued during hospitalization, and heparin was continued for 48-78 h, maintaining an activated thromboplastin time of 50-75 s. 15 Blood samples were collected on admission, every 3 h for the first 24 h, every 6 h for the next 2 days, and then daily until discharge. Adverse outcomes were defined as in-hospital death, intracerebral hemorrhage, recurrent ischemic events with ST-segment elevation, re-infarction and bleeding complication requiring or not requiring transfusion. Re-infarction was defined as re-elevation of creatine kinase (CK) and CK-MB levels because of a recurrence of ischemic events during hospitalization. Bleeding complications were defined as a decrease in blood hemoglobin level by 3 g/dl or more within 3 days after hospitalization. Data were analyzed according to the type of hospital (TEC or CHs) and the treatment strategy.
Statistical Analysis
Variables are expressed as mean ± standard deviation (SD). Variables were compared using a commercially available statistical software package (STATVIEW II, Abacus Concepts, Berkeley, CA, USA). The statistical significance of differences between groups was determined by one-way analysis of variance (ANOVA) and Scheffe's test as appropriate. Analysis for the cumulative frequency distribution was performed using Kaplan-Meier estimates and comparison of curves was by log-rank test. Differences were significant if the 2-sided p value was less than 0.05.
Results
Hospital Characteristics (Table 1) The major differences were that the TEC admits only patients who require emergency treatment and has at least one cardiologist available on a 24-h basis, whereas in the CHs the cardiology unit was part of another department and a cardiologist was not always available. The mean number of patients with AMI admitted to the TEC within 24 h of the onset was 3-fold that admitted to the CHs.
Patient Characteristics (Table 2)
There were no differences in patient characteristics among the 4 groups, according to hospital type and treatment strategy.
Angiographic Findings and Intervention Procedure Rates
At the TEC, TIMI flow grade 3 was present in 28% of the monteplase group and 10% of the primary PTCA group, and the patency rate (TIMI flow grade 2 or 3) was 56% in the monteplase group and 28% in the primary PTCA group (p<0.01) at the first angiogram (Fig 2) . There was no significant difference between these groups in the results at the final assessment: TIMI flow grade 3 was achieved in 91% of the monteplase group and 98% of the primary PTCA group. At the CHs, the overall trend was similar to that seen in the TEC: TIMI flow grade 3 was present in 46% and 7% of the monteplase and primary PTCA groups (p<0.01), and the patency rate (TIMI flow grade 2 or 3) was 62% and 17%, respectively (p<0.01) (Fig 2) . The final outcome was similar in the monteplase group and primary PTCA group, with TIMI flow grade 3 being achieved in 95% and 96%, respectively. Thus, the proportion of patients with a final TIMI flow of grade 3 did not differ between the 2 types of hospital or the 2 treatment strategies. PTCA was performed in 55% of the monteplase group and 91% of the primary PTCA group.
Time Factors Related to Reperfusion (Table 3)
Both the time from onset of symptoms to admission and the time from admission to cardiac catheterization were longer at the CHs than at the TEC, irrespective of treatment strategy. Furthermore, in the monteplase group, the time from admission to administration of monteplase was longer at the CHs than at the TEC. However, within each hospital type there was no time difference between the treatment strategies. The rates of TIMI flow grade 3 at 30, 60, 90, and 120 min after admission were, respectively, 12%, 46%, 95%, and 98% at the TEC and 4%, 24%, 56%, and 78% at the CHs; higher rates were achieved at the TEC up to 120 min after admission (30 min: p<0.07; 60, 90, and 120 min: p<0.01, respectively). Further analysis according to treatment showed that the rates of TIMI flow grade 3 at the TEC were 18%, 56%, 95%, and 97% in the monteplase group and 3%, 36%, 95%, 100% in the primary PTCA group. The rate of TIMI flow grade 3 was higher in the monteplase group 30 and 60 min after admission (p=0.02, p=0.07, respectively). At the CHs, the rates of TIMI flow grade 3 were 8%, 41%, 68%, and 84% in the monteplase group and 0%, 8%, 43%, and 70% in the primary PTCA group. The rate of TIMI flow grade 3 was higher in the monteplase group up to 90 min after admission (30 min: p=0.07; 60 min: p<0.01; 90 min: p=0.04) (Fig 3) . However, monteplasetreated patients at the CHs had a slightly higher rate of TIMI flow grade 3 up to 60 min after admission than did primary PTCA-treated patients at the TEC, although the difference did not reach statistical significance.
Infarct Size
The peak CK concentration, used as an index of infarct size, did not differ according to hospital type (3,014±2,400 mU/ml at the TEC vs 3,373±2,629 mU/ml at the CHs), but was lower in the monteplase group than in the primary PTCA group (2,789±2,230 mU/ml vs 3,517±2,721 mU/ml, p=0.07). When the peak CK concentration was further analyzed according to hospital type, there was no difference between the monteplase and primary PTCA groups at the TEC (2,748±2,191 mU/ml vs 3,300±2,606 mU/ml, p=0.30), whereas the value was slightly, but not significantly, lower in the monteplase group than in the primary PTCA group at the CHs (2,903±2,306 mU/ml vs 3,795± 2,852 mU/ml, p=0.14).
Adverse Outcomes (Table 4)
In this study, there were no in-hospital deaths, re-infarction or cerebral hemorrhages. Only 3 patients in the monteplase group at the CHs had recurrent ischemic events with ST-segment re-elevation, requiring immediate PTCA. Bleeding complications requiring transfusion occurred in only 1 patient in the primary PTCA group at the TEC. The rate of bleeding complications not requiring transfusion was less than 5% in both hospital types and with both treatment strategies.
Discussion
The present study demonstrated that an antecendent low dose of mutant t-PA with planned rescue PTCA produced an earlier patency than did primary PTCA, with regard to time to reperfusion, especially at CHs.
Although it has been established that reperfusion therapy for AMI improves clinical outcome, 1 treatment efficacy depends largely on rapid restoration and maintenance of blood flow of the IRA. 2, 3, 16, 17 When compared with PTCA, thrombolytic therapy has several disadvantages, including lower success rates (TIMI flow grade 3) and higher incidences of ischemic events after reperfusion and bleeding complications. However, thrombolytic therapy does have the advantage of ease of use. Primary PTCA does not have the disadvantages of thrombolytic therapy, but must be performed by experienced physicians at medical facilities equipped for the procedure. The advantages and drawbacks of different reperfusion strategies have led to controversial results. Randomized studies in the United States and Europe have reported that PTCA is superior to intravenous thrombolysis, 2,3 whereas observational studies, including the data from CHs, have shown no difference in mortality between the 2 approaches. [4] [5] [6] To date no consensus has been reached as to which approach consistently offers a sustained benefit. Because the advantages and disadvantages of thrombolytic therapy and primary PTCA are complementary, the PACT trial recently investigated the combined use of both treatments. 8 The results of that trial show that patients who received antecedent low doses of t-PA had more frequent early recanalization, which facilitated greater left ventricular function preservation with no augumentation of adverse events. We also reported a similar result. 9 Thrombolytic therapy followed by planned rescue PTCA has thus attracted attention as a new treatment option. In the emergency treatment of AMI, the capability of the operator and the site facilities are critical. With primary PTCA, the number of procedures performed in the hospital and the time from admission to the first balloon inflation influence outcome, whereas the outcome of thrombolytic therapy is unrelated to the number of procedures done at the hospital. 7, 18 To date, however, there has not been a direct comparison of reperfusion strategies according to type of hospital. In the present study, we found that the times from admission to monteplase treatment, cardiac catheterization, and reperfusion were all longer at the CHs and can be attributed to the protocols and policies at CHs, where cardiologists are not available in the emergency department 24 h a day. 19 Consequently, only 43% of the patients who received primary PTCA at the CHs achieved reperfusion within 90 min after admission, as targeted by the American College of Cardiology-American Heart Association (ACC/AHA) practice guidelines. 15 In contrast, 68% of patients at CHs who received monteplase before PTCA achieved reperfusion within 90 min after admission and, furthermore, in their groups the reperfusion rate up to 60 min after admission was slightly higher than that in patients who received primary PTCA at the TEC. This higher TIMI grade flow rate in patients who received antecendent monteplase soon after admission was considered important, especially among those who presented within 2 h of onset, as this time period is crucial to infarct size. 20 Hospitals that do not have a high volume of PTCA procedures tend to produce poor outcomes. 7 We found that antecedent monteplase effectively restored peripheral blood flow in the IRA, which then facilitated the PTCA procedure. 21, 22 Consequently, monteplase followed by PTCA was effective at both the TEC and the CHs equipped to perform PTCA. Another study has reported that, in general, clinical practice physicians in emergency rooms vacillate between choosing primary PTCA and thrombolytic therapy, which in turn worsens outcome. 11 One of the reasons for the reluctance to administer thrombolytic therapy is the increased incidence of bleeding complications. However, our study and the PACT trial showed no increase in bleeding complications as compared with patients undergoing primary PTCA, perhaps because of the low dose of thrombolytic agent administered. 8 These findings thus indicate that for patients with ST-segment elevation in whom thrombolysis is not contraindicated, including those scheduled to undergo primary PTCA, a low dose of thrombolytic agent should be administered immediately after diagnosis. Furthermore, this strategy may be more effective at CHs because of the higher TIMI 3 rate achieved at 30, 60, and 90 min after admission despite a longer time to monteplase administration compared with a TEC.
Study Limitations
First, the number of patients enrolled was small, but they were equally allocated to the 4 study groups, and significant differences were detected in reperfusion time according to hospital type and treatment strategy. Patients older than 70 years, who account for the majority of patients with AMI, were excluded and so the effectiveness of thrombolytic therapy followed by PTCA remains unclear in that age group.
Another limitation was that long-term outcomes were not investigated. In addition, the incidence of in-hospital events, including death, did not differ between the 2 treatment groups, which may be ascribed to enrollment of only patients who had a first AMI and exclusion of those with shock. However, the peak CK concentration, used as an index of infarct size, was slightly lower in the patients treated with antecedent monteplase in both hospital types.
The patients assigned to thrombolytic therapy received a fixed dose of 800,000 units of monteplase (half the standard dose), regardless of body weight. Whether this dose was adequate or not remains a matter of debate.
The final TIMI flow grade 3 rate in our study was higher than previously reported rates and may be related to the fact that TIMI flow grade 0 was not confirmed angiographically at the time of thrombolytic treatment. In addition, the evaluation of TIMI flow grade is largely subjective. However, approximately the same numbers of patients received either thrombolytic therapy or primary PTCA at each type of hospital, so we consider that the difference in patency rates among the 4 groups is acceptable.
Finally, a glycoprotein IIb/IIIa inhibitor was not used in this study. The TIMI 14 study showed that earlier and higher patency rates were obtained in patients treated with a glycoprotein IIb/IIIa inhibitor plus t-PA. 23 This new treatment strategy, followed by early percutaneous coronary intervention, may be more effective than primary PTCA alone, particularly at CHs. 22 
Conclusions
In patients with AMI, an antecedent low dose of mutant t-PA with planned rescue PTCA produced a higher patency rate early after admission than did PTCA without t-PA administration. The benefits of thrombolytic therapy followed by planned rescue PTCA were more marked at CHs than at the TEC, and included a slightly smaller infarct size, with no increase in bleeding complications.
